Bioarctic Ab Stock Annual Yield
BIOA-B Stock | SEK 189.60 4.20 2.27% |
BioArctic AB fundamentals help investors to digest information that contributes to BioArctic's financial success or failures. It also enables traders to predict the movement of BioArctic Stock. The fundamental analysis module provides a way to measure BioArctic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioArctic stock.
BioArctic |
BioArctic AB Company Annual Yield Analysis
BioArctic's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
Competition |
In accordance with the recently published financial statements, BioArctic AB has an Annual Yield of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all Sweden stocks average (which is currently at 0.0).
Did you try this?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
All Next | Launch Module |
BioArctic Fundamentals
Return On Equity | -0.0142 | |||
Return On Asset | -0.0055 | |||
Profit Margin | (0.05) % | |||
Operating Margin | (0.03) % | |||
Current Valuation | 26.19 B | |||
Shares Outstanding | 73.73 M | |||
Shares Owned By Insiders | 48.40 % | |||
Shares Owned By Institutions | 30.39 % | |||
Price To Earning | 12.95 X | |||
Price To Book | 32.29 X | |||
Price To Sales | 111.27 X | |||
Revenue | 23.15 M | |||
Gross Profit | 155.53 M | |||
EBITDA | (126.63 M) | |||
Net Income | (119.79 M) | |||
Cash And Equivalents | 848.4 M | |||
Cash Per Share | 13.84 X | |||
Total Debt | 7.79 M | |||
Debt To Equity | 3.00 % | |||
Current Ratio | 5.62 X | |||
Book Value Per Share | 8.92 X | |||
Cash Flow From Operations | (140.46 M) | |||
Earnings Per Share | 0.31 X | |||
Target Price | 393.2 | |||
Number Of Employees | 61 | |||
Beta | 0.61 | |||
Market Capitalization | 26.34 B | |||
Total Asset | 897.73 M | |||
Net Asset | 897.73 M |
About BioArctic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioArctic AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioArctic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioArctic AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in BioArctic Stock
BioArctic financial ratios help investors to determine whether BioArctic Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioArctic with respect to the benefits of owning BioArctic security.